Future Cardiol. 2026 Feb 20:1-7. doi: 10.1080/14796678.2026.2633969. Online ahead of print.
ABSTRACT
BACKGROUND: MASLD is a prevalent liver condition linked to increased cardiovascular risks and higher mortality, particularly among those with AMI. This study explores the impact of MASLD on clinical outcomes in patients with AMI, focusing on mortality, hospital charges, and length of stay.
METHODS: The NIS database from 2018 to 2020 was utilized to evaluate the prevalence, mortality, costs, and resource use related to primary AMI hospitalizations with and without MASLD.
RESULTS: A total of 1,885,105 hospitalizations with AMI were identified, with 39,000 (2.1%) patients having AMI and MASLD. The mean length of hospital stay was significantly longer in AMI patients with MASLD (5.58 days) compared to those without MASLD (4.34 days) (p < 0.001). In-hospital mortality was significantly higher in patients with MASLD (7.8%) compared to those without (4.6%), with 45% increased odds of mortality (OR: 1.45, p < 0.001). The hospital charges were also higher for patients with MASLD ($128,494) compared to non-MASLD patients ($104,836) (p < 0.001), with regression analysis indicating an additional $9,911 in charges (p < 0.001).
CONCLUSIONS: AMI patients with MASLD experience higher mortality rates, longer hospital stays, and increased healthcare costs. Further research is essential to develop improved management strategies.
PMID:41720751 | DOI:10.1080/14796678.2026.2633969